The Medical Briefing  Nephrology

Diabetes and chronic kidney disease: 2026 KDIGO guidelines

Guidelines · KDIGO 2026 · draft

At a glance

■ Diabetes and CKD · KDIGO 2026 (draft)
SGLT2 inhibitors and GLP-1-based therapies first (1A), metformin as second line, finerenone as a strong recommendation in T2D: earlier cardio-renal triple therapy.